Ferring Pharmaceuticals v. Fresenius Kabi: Degarelix Patent Appeals Voluntarily Dismissed
Ferring Pharmaceuticals and affiliated co-plaintiffs voluntarily dismissed Federal Circuit appeals covering eight patents on degarelix manufacture and GnRH antagonist-based prostate cancer treatment. The dismissal under Fed. R. App. P. 42(b), with each side bearing its own costs, closed a 483-day appellate proceeding without any merits ruling.
Eight degarelix patents exit Federal Circuit without a merits ruling
Case 23-1460 was filed at the Court of Appeals for the Federal Circuit on 3 February 2023, bringing together Ferring Pharmaceuticals, Inc., Fresenius Kabi USA, LLC, Ferring International Center S.A., Polypeptide Laboratories AS, and Ferring B.V. as appellants in a consolidated infringement action. The eight patents at issue — spanning US8841081B2, US8828938B2, US9415085B2, US9579359B2, US9877999B2, US10695398B2, US10729739B2, and US10973870B2 — collectively cover the manufacture of degarelix, a GnRH antagonist, and its clinical application in treating metastatic and hormone-sensitive prostate cancer.
The appeals were closed on 31 May 2024 when the parties filed a joint stipulation of dismissal under Federal Rule of Appellate Procedure 42(b). The court ordered dismissal accordingly, with each side bearing its own costs. Because this is a voluntary procedural dismissal rather than a merits adjudication, the Federal Circuit issued no ruling on the validity or infringement of any of the eight patents. The public record does not disclose whether the parties reached a confidential settlement or simply agreed to end the appellate proceedings on other grounds.
A 483-day appellate lifespan followed by agreed dismissal is consistent with parties resolving underlying commercial or licensing disputes through a confidential agreement reached ahead of briefing completion or oral argument. The symmetric cost order — each side bearing its own — suggests neither party conceded fault and is consistent with a negotiated exit. What drove the resolution, including any licensing terms, market access arrangements, or commercial concessions relating to degarelix products, remains unknown from publicly available records.
Filing to Voluntary dismissal in 483 days
483 days at the Federal Circuit — appellate proceedings typically resolve in 12–18 months
Voluntarily dismissed: what the Fed. R. App. P. 42(b) exit means for both parties
Fed. R. App. P. 42(b): a consensual procedural exit
Rule 42(b) permits parties to dismiss an appeal by filing a signed agreement. Unlike a district-court Rule 41 dismissal, it carries no automatic with/without-prejudice designation at the appellate level — it simply terminates the appeal. The Federal Circuit entered the dismissal by order, meaning no opinion issued and no precedent was set on degarelix patent validity or infringement.
No merits rulingThe public record is silent on prejudice status
A Rule 42(b) appellate dismissal does not carry the same with/without-prejudice framework that governs district-court voluntary dismissals. The order simply states the appeals are dismissed with each side bearing its own costs. Whether the underlying district-court judgment remains in effect, was vacated by agreement, or is subject to further proceedings is not disclosed in the publicly available Federal Circuit docket.
Prejudice status undisclosedEight degarelix patents exit appellate review unresolved
Because no merits ruling issued, none of the eight patents was affirmed, invalidated, or found infringed at the appellate level. The patents remain in force unless and until challenged through inter partes review, reexamination, or future litigation. For Ferring and its affiliates, the portfolio retains its nominal scope but has not received Federal Circuit validation.
Patent status unchangedDegarelix IP landscape stays unsettled for the sector
The absence of a Federal Circuit opinion means no public guidance on the validity or claim scope of these degarelix and GnRH antagonist patents. Generic and biosimilar developers considering degarelix products should treat these eight patents as live enforcement risks. Any private resolution between the parties — if one occurred — may have established licensing terms that are not publicly visible but could affect market entry timing.
Monitor for re-litigationFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ferring Pharmaceuticals, Inc. | Company | Pharmaceutical patent holders — manufacturers and licensors of degarelix GnRH antagonist therapySearch in Eureka ↗ |
| Co-Plaintiff | Fresenius Kabi USA, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Ferring International Center S.A. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Polypeptide Laboratories, AS | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Ferring B.V. | Individual | Search in Eureka ↗ |
| Defendant | Defendant | Individual | No named defendant recorded in the public Federal Circuit docket for this caseSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Wharton | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christian E. Mammen | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dana Kathryn Severance | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John Benedict Bourke | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joshua Davis | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mary W. Bourke | Attorney | Counsel for Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Womble Bond Dickinson (US) LLP | Law Firm | Representing Ferring Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order recites that the parties ‘having so agreed’ consented to dismissal under Fed. R. App. P. 42(b), with each side bearing its own costs. This phrasing confirms a fully consensual exit — neither party was compelled to dismiss. Critically, no substantive analysis of any claim, prior art argument, or infringement allegation is contained in the order, meaning the ruling carries no precedential or persuasive weight on the merits of the eight degarelix and GnRH antagonist patents at issue.
US9579359B2 and 7 further patents — degarelix manufacture and GnRH antagonist therapy
The eight patents span a tightly clustered family covering the synthesis, formulation, and clinical use of degarelix — a synthetic decapeptide GnRH antagonist used for androgen deprivation in prostate cancer. Application dates range from the early 2010s through 2020, reflecting iterative prosecution across manufacturing methods, dosing regimens, and patient population claims. The technical domain sits at the intersection of peptide chemistry, oncology pharmacology, and pharmaceutical manufacturing, with claims directed at both the compound’s production and its clinical indication.
For the oncology and urology therapeutics sector, this eight-patent cluster represents a significant enforcement portfolio around degarelix — a product with substantial commercial value in hormone-sensitive and metastatic prostate cancer markets. The multi-assignee structure across Ferring entities and Polypeptide Laboratories suggests the IP spans both API manufacturing and finished-product commercialisation. Competitors — including generic drug developers filing Paragraph IV certifications and biosimilar sponsors — face a portfolio that has not been narrowed or invalidated by any court of record as of this dismissal.
Should you run an FTO against the Ferring degarelix patent portfolio?
Any company developing, manufacturing, or commercialising degarelix formulations, GnRH antagonist peptides for prostate cancer, or related androgen deprivation therapies should treat all eight patents as active risks. The Federal Circuit dismissal created no claim narrowing, no invalidity finding, and no safe harbour. This applies equally to API manufacturers, finished-dose developers, authorised generic sponsors, and contract manufacturers in the degarelix supply chain.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map product features against all eight patent claim sets simultaneously, identify prosecution history estoppel across the family, and flag related divisional or continuation applications that may extend the portfolio’s reach. Use Eureka to benchmark claim scope against prior art that was never adjudicated in this appeal and to prioritise IPR petition targets before any commercial launch decision.
Run a freedom-to-operate analysis on US9579359B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent appeals in oncology and GnRH antagonist technology
Explore comparable Federal Circuit infringement appeals involving GnRH antagonist peptides, prostate cancer therapeutics, and multi-patent pharmaceutical portfolios dismissed or decided at the appellate level.
What this case signals for the oncology and GnRH antagonist IP landscape
A voluntary Federal Circuit exit across eight patents without a merits ruling leaves significant competitive uncertainty for degarelix market participants.
All eight patents remain live enforcement risks post-dismissal
No invalidity or non-infringement ruling issued. Any company developing, manufacturing, or commercialising degarelix formulations or GnRH antagonist prostate cancer therapies should conduct a fresh FTO review against all eight patents. The dismissal does not narrow claim scope or create any estoppel.
Symmetric cost order is consistent with a confidential settlement signal
When both parties agree to dismiss and split costs, it typically signals a negotiated resolution rather than a unilateral concession. Companies monitoring the degarelix space should watch for licensing disclosures, product launch delays, or authorised generic arrangements that may surface indirectly.
Ferring v Defendant — key questions answered
The Federal Circuit voluntarily dismissed the consolidated appeals under Fed. R. App. P. 42(b) on 31 May 2024, with each side bearing its own costs. The parties jointly agreed to the dismissal, and no merits ruling on the eight degarelix and GnRH antagonist patents was issued.
Eight patents were at issue: US8841081B2, US8828938B2, US9415085B2, US9579359B2, US9877999B2, US10695398B2, US10729739B2, and US10973870B2. They collectively cover the manufacture of degarelix, GnRH antagonist formulations, and methods of treating metastatic and hormone-sensitive prostate cancer.
No. A Rule 42(b) voluntary dismissal carries no merits adjudication. The Federal Circuit issued no opinion on validity, claim scope, or infringement. All eight patents remain in force and represent active enforcement risks for competitors in the degarelix and GnRH antagonist market.
Rule 42(b) terminates the specific appeal by mutual agreement. It does not function as a with-prejudice dismissal that bars re-filing in the same way a district court Rule 41 dismissal might. The patents remain enforceable, and the patent holders could initiate new infringement proceedings in district court or through the ITC, subject to any private agreements between the parties.
The plaintiffs-appellants were Ferring Pharmaceuticals, Inc., Fresenius Kabi USA, LLC, Ferring International Center S.A., Polypeptide Laboratories AS, and Ferring B.V. They were represented by Womble Bond Dickinson (US) LLP. No defendant is publicly named in the Federal Circuit docket for this case number.
PatSnap Eureka searches patents and litigation data to answer instantly.